Engflag

Bactiv

Quick links to important sections

Bactiv

Bactiv_FR

Method of action: Antibacterial Broad Spectrum (Bactericidal), Bactericidal, Bactericidal Broad Spectrum

Treatment option: Abortion, Abscess, Lung Abscess, Bronchitis, Bronchopneumonia, Vaginitis, Community Acquired Pneumonia, Gonorrhea, Dysentery, Impetigo

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bactiv

Property Description
Active Ingredients Amoxicillin, Clavulanic acid
Form Tablet, Suspension, Powder for Injection
Pharmacological Class Antibiotic / beta-Lactamase Inhibitor Combination
General Purpose Management of bacterial infections
Origin Semisynthetic (Amoxicillin) & Synthetic (Clavulanic acid)

The Identity and Classification of Co-amoxiclav

The medicine known commercially as Bactiv is the dual-component drug entity designated internationally as Co-amoxiclav (Amoxicillin and Clavulanic acid). It is strictly a prescription-only (Rx) medication that belongs to the Pharmacological class of Antibiotic (beta-Lactam) / beta-Lactamase Inhibitor Combinations. This classification is recognized by authoritative bodies worldwide and distinguishes it from single-agent penicillins. The combination is considered one of the most frequently prescribed antibiotics for treating a range of bacterial infections. This fixed-dose combination product is broadly recognized for its utility across various patient groups, from pediatric patients requiring the oral suspension to adults using the tablet forms.

Composition, Origin, and Available Forms

The core of Bactiv consists of two primary active ingredients: the semisynthetic antibiotic Amoxicillin and the synthetic beta-lactamase inhibitor Clavulanic acid (supplied as its potassium salt). The Amoxicillin is a derivative of penicillin, while Clavulanic acid is synthesized. The medication is offered in several high-level dosage form(s) to ensure versatility: Oral forms like the Tablet and Powder for Oral Suspension, and the Sterile Powder for Injection for required Intravenous (I.V.) administration in acute care settings.

General Purpose and Unique Therapeutic Benefit

The general purpose of the Amoxicillin/Clavulanic acid combination is the effective management of bacterial infections caused by susceptible organisms. The unique feature and therapeutic benefit of the drug lie in the Clavulanic acid component, which acts as a shield to protect the antibiotic. The protective role of clavulanate is essential for restoring the activity of amoxicillin against bacteria that produce the resistance enzyme beta-lactamase. This mechanism allows the combination to combat bacterial strains, such as those that cause infections like pneumonia, that might otherwise be resistant.

What side effects are possible with Bactiv?

Possible Side Effects and Safety Information

The safety profile of Bactiv (Co-amoxiclav) is characterized by adverse reactions that are officially classified by frequency, reflecting data from government regulatory authorities such as the FDA and EMA. The most frequently documented reactions primarily affect the Gastrointestinal System.

Frequency and System Classifications

Adverse reactions are classified by frequency as observed in official regulatory documents:

  • Common reactions (e.g., in 1 to 10 out of 100 patients) include diarrhea, nausea, vomiting, and mucocutaneous candidiasis.
  • Uncommon reactions include dizziness, headache, indigestion, and temporary increases in hepatic enzymes (AST and/or ALT).

Other documented effects involve the Skin (e.g., rash) and Blood and Lymphatic System (e.g., reversible leukopenia) and are typically classified as Rare or Very Rare.

Serious Adverse Reactions and Restrictions

Regulatory labeling highlights specific Serious Adverse Reactions that are important for risk assessment. These include severe, potentially fatal hypersensitivity reactions such as anaphylaxis, as well as severe skin disorders like Stevens-Johnson Syndrome (SJS). Events affecting the Hepatobiliary System, such as hepatitis and cholestatic jaundice, are also documented, and these signs may not become evident until several weeks after treatment has ceased.

Due to this risk, the medicine is formally contraindicated in patients with a history of Co-amoxiclav-associated hepatic dysfunction or prior severe immediate hypersensitivity to any beta-lactam agent. Furthermore, specific safety considerations apply to patients with renal impairment, where dosage adjustment is required to mitigate the risk of CNS effects.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Bactiv

Overdose scope

Feature Description (Strictly Regulatory-Based)
Documented overdose presentations Gastrointestinal signs (vomiting, diarrhea, stomach pain) and CNS effects like sleepiness or convulsions.
Physiological systems affected (as stated in label) Gastrointestinal, Renal (urinary tract), and Central Nervous System (CNS).
Dose-related or exposure-related factors (if applicable) High doses or overdose, particularly in settings of reduced urine output, increase the risk of amoxicillin crystalluria.
Population-specific overdose notes (if applicable) Patients with impaired renal function face a higher risk of seizures and crystalluria due to slower drug clearance.
Emergency-response statements (as written in official documents) Seek immediate medical attention for any symptoms of overdose.
When immediate medical help is required (label-derived phrasing only) Urgent medical help is required if symptoms of overdose occur, especially for convulsions, severe vomiting, or signs of collapse.

Overdose classifications (high-level)

Classification Aspect Description (Strictly Regulatory-Based)
Severity classification (as defined in official documents) Overdose may lead to severe outcomes such as amoxicillin crystalluria resulting in acute renal failure and disturbances of fluid and electrolyte balances.
Regulatory basis (EMA / FDA / etc.) Based on authoritative Prescribing Information and Summary of Product Characteristics (SmPC) from government health agencies.
Overdose-context constraints (as defined in official documents) Management is generally symptomatic and supportive, with the option for drug removal via haemodialysis.

Resulting overdose structure

Official overdose statements:

  • Overdose commonly presents with gastrointestinal symptoms and may include signs like sleepiness and decreased urination.
  • Convulsions or seizures have been documented, primarily in patients with impaired kidney function.
  • Management includes drug discontinuation, provision of symptomatic and supportive care, and ensuring adequate fluid intake to reduce the possibility of crystalluria.
  • Haemodialysis is noted as a procedure that can remove the active components from circulation.

Connection to the overall overdose profile (3 sentences): Regulatory documents define the overdose profile for Bactiv through specific clinical manifestations affecting the gastrointestinal, renal, and central nervous systems. The officially mandated emergency actions require immediate medical attention for any presentation of these symptoms. Management procedures are structured around supportive care, preventing crystalluria, and the use of haemodialysis to reduce drug concentrations, as described in authoritative prescribing information.

Therapeutic Uses of Bactiv

What Bactiv Treats: Main Uses and Benefits

Bactiv (Co-amoxiclav) is commonly used to treat a range of bacterial infections. It provides support in addressing the underlying bacterial cause, and is relevant for managing conditions marked by increased physiological stress from bacteria. There are several key therapeutic areas where this medication is applicable.

It is primarily applied in addressing infections of the lower respiratory tract (such as community-acquired pneumonia), acute otitis media, sinusitis, infections of the skin and soft tissue, and urinary tract infections. It is relevant in clinical settings that involve acute or unstable symptom patterns, such as pronounced symptoms including high fever, localized pain, and purulent sputum production. This use is helpful in situations requiring additional symptomatic assistance.

Quick Fact: Symptom Relief Support

Bactiv is commonly used to help manage acute, localized pain and swelling associated with infections like cellulitis and dental abscesses. Its supportive action assists in easing the acute discomfort and functional strain caused by these conditions, contributing to improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

Who can and cannot use Bactiv?

This medicine is a combination of amoxicillin and clavulanate potassium. Eligibility for use is strictly determined by documented governmental regulatory information.

Populations that Must Not Use Bactiv (Contraindications)

Classification Populations
Allergy Individuals with a known hypersensitivity or severe allergic reaction to penicillins or other beta-lactam antibiotics (e.g., cephalosporins).
Liver History Patients with a prior history of jaundice or hepatic dysfunction specifically associated with previous use of Bactiv (Co-Amoxiclav) or any penicillin.

Restrictions and Special Considerations

Classification Eligibility Rules
Mononucleosis Use is generally avoided in patients with a suspected or confirmed diagnosis of infectious mononucleosis due to a high risk of developing a rash.
Renal Impairment Patients with severe renal impairment (e.g., glomerular filtration rate less than 30 mL/ min) generally require dose adjustment or must not use certain extended-release tablet strengths.
Liver Impairment Use requires caution and close monitoring in patients with pre-existing hepatic disease.
Age/Weight Specific oral tablet forms are typically not recommended for children weighing less than 40 kg. Pediatric use for infants and younger children relies on weight-based dosing for suspensions.
Pregnancy/Lactation Use is generally avoided during pregnancy, especially the first trimester, unless deemed essential by a healthcare professional. It may be administered during the period of lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interactions for Bactiv (Co-amoxiclav, Amoxicillin and Clavulanic acid), based strictly on government regulatory prescribing information.

Documented Drug-Drug Interactions

Interacting Substance Official Regulatory Statement Practical Implication
Probenecid Concurrent use is not recommended; Probenecid decreases the renal tubular secretion of Amoxicillin, resulting in increased and prolonged blood concentrations. This pharmacokinetic interaction dictates avoiding co-administration to manage Amoxicillin exposure.
Oral Anticoagulants (e.g., Warfarin) May lead to an abnormal prolongation of prothrombin time (increased INR). Appropriate monitoring of INR and potential dose adjustment of the anticoagulant are necessary.
Allopurinol Co-administration increases the incidence of a rash. This population-specific interaction requires caution in patients receiving both drugs.
Oral Contraceptives May reduce the efficacy of combined oral estrogen/progesterone contraceptives. Alternative or additional non-hormonal methods may be considered due to this exposure-modifying interaction.

Interactions with Food and Lab Tests

The absorption of the Clavulanate potassium component is officially stated to be enhanced when Bactiv is administered at the start of a meal. The medicine can interfere with certain lab procedures; high concentrations of Amoxicillin may cause false-positive results with non-enzymatic urine glucose tests, and Bactiv can cause a false-positive direct Coombs test.

Mechanism of Action

Inhibiting Bacterial Cell Wall Construction

This domain describes how the core antibiotic, Amoxicillin, works by targeting the Peptidoglycan Synthesis Pathway. It acts as an irreversible inhibitor of bacterial Penicillin-Binding Proteins (PBPs), which are the enzymes responsible for creating the structural cross-links in the cell wall. This targeted disruption initiates the process of bacterial cell lysis and death in susceptible organisms, a physiological consequence of the drug's mechanism. The action results in a reduction of the pathogenic bacterial load, a physiological effect resulting from bacterial lysis.

Overcoming Bacterial Resistance (Enzyme Shielding)

This mechanistic domain is governed by Clavulanic Acid, which addresses bacterial defense. It functions as an irreversible "suicide" inhibitor of bacterial \beta-Lactamase Enzymes that would otherwise inactivate Amoxicillin. By inactivating these destructive enzymes, the Clavulanic Acid component effectively restores and extends the access of Amoxicillin to its target, thereby allowing the drug to reduce the pathogenic load against a broader spectrum of bacteria, including resistant strains.

Dosage and Administration Information

Bactiv (Co-amoxiclav) is administered through two primary, approved routes: the Oral route, utilizing tablets or reconstituted suspension, and the Intravenous (IV) route, which uses a sterile powder for injection in acute care settings. This flexibility allows for sequential therapy, transitioning from IV to oral forms when appropriate.

For adults weighing 40 kg or more, oral dosing commonly follows two patterns: 875 mg/125 mg (Amoxicillin/Clavulanic acid) taken every 12 hours or 500 mg/125 mg taken every 8 hours, depending on the severity of the infection. A key instruction involves the timing of oral intake: Bactiv should be administered at the start of a meal. This timing is designed to enhance absorption and minimize the potential for gastrointestinal intolerance.

Treatment is typically delivered over a course of 5 to 14 days, and the duration should not be extended past 14 days without formal clinical re-evaluation. Dosing is adjusted based on specific patient conditions; modification is required for patients with significantly reduced kidney function, specifically a Creatinine Clearance (CrCl) of 30 mL/ min or less. Furthermore, specific forms, such as extended-release tablets, must be swallowed whole and cannot be crushed, broken, or chewed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bactiv

Evidence for use in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

The research examining Bactiv for conditions characterized by functional limitations, such as Acute Bacterial Skin and Skin Structure Infections (ABSSSI), primarily involves short-term randomized controlled trials (RCTs). In these studies, researchers observed populations with documented ABSSSI to monitor outcomes related to systemic or functional imbalance. Specifically, studies explored how symptoms evolved in the observed populations, with outcomes related to physical discomfort and the assessment of infection status being the primary focus.

The findings describe patterns observed in the studies related to the monitoring of changes in fever and signs of inflammation and the achievement of other clinical endpoints. Research highlights changes measured during the short-term study period, often within the first few days after treatment began.

Evidence for use in Other Bacterial Infections (e.g., Sinusitis, Otitis Media, UTIs)

Bactiv was evaluated in research exploring a wide range of other bacterial infections, which are conditions characterized by fluctuating or episodic manifestations. Studies exploring short-term symptom changes for these conditions often included RCTs and systematic reviews that examined Bactiv against a placebo or other active antimicrobial agents. Research examined outcomes related to physiological strain or stress, such as the monitoring of changes in patient-reported pain and the monitoring of changes in inflammatory states.

What is Still Uncertain About Bactiv Research

The research landscape highlights key areas where certainty remains low. The limitations include that follow-up durations were limited, and long-term outcomes are not fully established. Comparative evidence is lacking against all possible standard treatments. The evidence quality varies across studies, and results apply only to the populations studied under the specific conditions of the research. Data for certain groups, such as those with severe underlying conditions, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Bactiv (FAQ)

Q: What is Bactiv used to treat?

According to the official product information, Bactiv is approved for treating certain serious bacterial infections. Specifically, it is indicated for infections that have been shown to be caused by susceptible bacteria. Official sources confirm its use in specific situations where a potent antibacterial action is required.

Q: How quickly does Bactiv start working?

Regulatory sources suggest that, due to its intravenous administration, Bactiv can reach the site of infection rapidly to begin its action against susceptible bacteria. The rate at which a patient observes clinical improvement can vary, depending on the specific type and severity of the infection being treated.

Q: Can Bactiv be used for children?

Regulatory documents state that Bactiv can be used in pediatric patients, but only for certain infections and specific age groups. The decision to use it in children depends on the infection type and the child's weight, following careful attention to the official dose recommendations. Use in newborns, particularly those with certain risk factors, may be restricted.

Q: What happens if I miss a dose of Bactiv?

Since Bactiv is typically administered in a hospital or clinical setting, dose management is handled by healthcare professionals. The official product information emphasizes the need for continuous administration to maintain effective concentrations. Any changes to the dosing schedule are determined and managed by the prescribing healthcare team.

Q: Can I drink alcohol while taking Bactiv?

Official product information suggests that consuming alcohol while receiving Bactiv may increase the risk of certain side effects, particularly those affecting the nervous system. Questions regarding alcohol consumption during therapy should always be directed to a healthcare professional to ensure safety and compliance with the treatment plan.

How should Bactiv be stored and disposed of?

How to Store and Dispose of Bactiv (Co-Amoxiclav)

Official regulations define specific storage and disposal requirements for Bactiv depending on the dosage form.

Storage Requirements

Dosage Form Temperature/Conditions Stability Constraint
Tablets / Dry Powder Store at 20 C to 25 C and protect from moisture. Store away from excessive heat.
Reconstituted Suspension Must be refrigerated (2 C to 8 C); Do not freeze. Stable for 10 days only.

All forms of the medicine must be stored out of the sight and reach of children. The dry powder for oral suspension must be kept tightly closed.

Disposal Instructions

Unused or expired Bactiv must not be discarded in household trash or disposed of via the sink or toilet. Proper disposal requires returning the product to a pharmacy-led take-back program or a local pharmaceutical collection point, as directed by official environmental waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPhilippines

Equivalent of Bactiv found in:

A-Z Index: